JLP-2004 is under clinical development by Jeil Pharmaceutical and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JLP-2004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JLP-2004 overview
JLP-2004 is under development for the treatment of pain, osteoarthritis, rheumatoid arthritis, back pain. The drug candidate is an incrementally modified drug (IMD). It acts by targeting cyclooxygenase type 2 (Cox-2). It is administered through oral route as tablets.
Jeil Pharmaceutical overview
Jeil Pharmaceutical (Jeil), is a pharmaceutical company which carries out research, development, manufacturing and commercialization of active pharmaceuticals and finished dosage forms. Its product portfolio includes solid medicines and injections, finished pharmaceutical products including patches and active pharmaceutical ingredients (APIs). The company offers APIs in the therapeutic areas of antibiotic, oncology, cardiovascular, urology, gastrointestinal, antiviral and respiratory, among others. Jeil exports synthetic ingredients such as Cefditoren Pivoxil and Epinastine HCl, among others to Japan and China. It also exports over the counter products such as Kefentech Plaster and Sanyplast in ASEAN countries, Central and South America, Africa, and other countries. The company operates a factory and research and development institute in Yongin-si, Gyeonggi-do, Korea. Jeil is headquartered in Seoul, South Korea.
For a complete picture of JLP-2004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
